Literature DB >> 15451784

Growth factors in the collateral circulation of chronic total coronary occlusions: relation to duration of occlusion and collateral function.

Gerald S Werner1, Enrico Jandt, Andreas Krack, Gero Schwarz, Oliver Mutschke, Friedhelm Kuethe, Markus Ferrari, Hans R Figulla.   

Abstract

BACKGROUND: Despite extensive animal experimental evidence, there are few data on the relation of growth factors and collateral function in humans. METHODS AND
RESULTS: In 104 patients with a chronic total coronary occlusion (CTO; >2 weeks' duration), collateral function was assessed invasively during recanalization by intracoronary Doppler and pressure recordings. A collateral resistance index, R(Coll), was calculated. Blood samples were drawn from the distal coronary bed supplied by the collaterals and from the aortic root to measure basic fibroblast growth factor (bFGF), monocytic chemotactic protein-1 (MCP-1), transforming growth factor-beta (TGF-beta), placenta growth factor (PlGF), and tumor necrosis factor-alpha (TNF-alpha). The bFGF concentration in the collateralized artery was higher than in the aortic root (34+/-20 versus 18+/-14 pg/mL; P<0.001). bFGF was highest in recent occlusions (2 to 12 weeks) with the highest R(Coll). Higher collateral concentrations were also observed for MCP-1, TGF-beta, and PlGF, but without a close relation to the duration of occlusion. TNF-alpha was not increased in collaterals compared with the systemic circulation. MCP-1, PlGF, and TGF-beta were significantly increased in small collaterals with the highest shear stress. Diabetic patients had lower bFGF and higher MCP-1 levels than nondiabetics.
CONCLUSIONS: In CTOs, the continuous release of bFGF into collaterals showed a close relation to the duration of occlusion and collateral function, which underscores its therapeutic potential. Other factors influencing growth factor release appeared to be shear stress for MCP-1, TGF-beta, and PlGF and the presence of diabetes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15451784     DOI: 10.1161/01.CIR.0000143624.72027.11

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

1.  Endocan: a novel biomarker associated with well-developed coronary collateral circulation in patients with stable angina and chronic total occlusion.

Authors:  Samim Emet; Ali Elitok; Imran Onur; Mehmet Kocaaga; Ahmet Kaya Bilge; Huseyin Oflaz; Berrin Umman; Aytac Oncul; Zehra Bugra; Kamil Adalet; Fehmi Mercanoglu
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

2.  Maternal and fetoplacental hypoxia do not alter circulating angiogenic growth effectors during human pregnancy.

Authors:  Stacy Zamudio; Marcus Borges; Lourdes Echalar; Olga Kovalenko; Enrique Vargas; Tatiana Torricos; Abdulla Al Khan; Manuel Alvarez; Nicholas P Illsley
Journal:  Biol Reprod       Date:  2014-02-27       Impact factor: 4.285

3.  Poor coronary collateral vessel development in patients with mild to moderate renal insufficiency.

Authors:  Shuang-lun Xie; Hai-yan Li; Bing-qing Deng; Nian-sang Luo; Deng-feng Geng; Jing-feng Wang; Ru-qiong Nie
Journal:  Clin Res Cardiol       Date:  2010-09-25       Impact factor: 5.460

Review 4.  Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors.

Authors:  Gabor M Rubanyi
Journal:  Mol Ther       Date:  2013-02-12       Impact factor: 11.454

5.  Cellular and molecular mechanism regulating blood flow recovery in acute versus gradual femoral artery occlusion are distinct in the mouse.

Authors:  Yagai Yang; Gale Tang; Jinglian Yan; Brian Park; Ari Hoffman; Guodong Tie; Rong Wang; Louis M Messina
Journal:  J Vasc Surg       Date:  2008-12       Impact factor: 4.268

6.  Elevated resistin opposed to adiponectin or angiogenin plasma levels as a strong, independent predictive factor for the occurrence of major adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over 1-year follow-up.

Authors:  Radoslaw Kreçki; Maria Krzemińska-Pakuła; Jan Z Peruga; Piotr Szcześniak; Piotr Lipiec; Karina Wierzbowska-Drabik; Daria Orszulak-Michalak; Jarosław Damian Kasprzak
Journal:  Med Sci Monit       Date:  2011-01

7.  Plasma chemokine levels are associated with the presence and extent of angiographic coronary collaterals in chronic ischemic heart disease.

Authors:  Ellen C Keeley; J Randall Moorman; Ling Liu; Lawrence W Gimple; Lewis C Lipson; Michael Ragosta; Angela M Taylor; Douglas E Lake; Marie D Burdick; Borna Mehrad; Robert M Strieter
Journal:  PLoS One       Date:  2011-06-22       Impact factor: 3.240

8.  Effect and mechanism of thrombospondin-1 on the angiogenesis potential in human endothelial progenitor cells: an in vitro study.

Authors:  Qing Qin; Juying Qian; Lei Ge; Li Shen; Jianguo Jia; Jianhao Jin; Junbo Ge
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

9.  Relationship between thrombospondin-1, endostatin, angiopoietin-2, and coronary collateral development in patients with chronic total occlusion.

Authors:  Qing Qin; Juying Qian; Jianying Ma; Lei Ge; Junbo Ge
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

10.  Influence of Obstructive Sleep Apnoea Severity on Coronary Collateral Recruitment During Coronary Occlusion.

Authors:  Usaid K Allahwala; Peter A Cistulli; Hasthi U Dissanayake; Michael Ward; James C Weaver; Ravinay Bhindi
Journal:  Lung       Date:  2021-08-10       Impact factor: 2.584

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.